---
title: "ClearPoint Neuro 2Q 2026: Revenue $10.88M, EPS $(0.38) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294740639.md"
description: "ClearPoint Neuro reported Q2 2026 revenue of $10.88M, an 18% year-over-year increase, driven by a 71% surge in neurosurgery sales. However, the company posted a net loss of $11.34M and a loss per share of $(0.38), widening from the prior year's figures. Year-to-date revenue reached $23.0M. The results reflect continued commercial expansion and operational scaling following the IRRAS integration."
datetime: "2026-08-03T21:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294740639.md)
  - [en](https://longbridge.com/en/news/294740639.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294740639.md)
generator: "portal-rs"
---

# ClearPoint Neuro 2Q 2026: Revenue $10.88M, EPS $(0.38) — 10-Q Summary

ClearPoint Neuro reported second-quarter 2026 results with revenue rising year over year but wider net losses and a larger loss per share versus the prior-year quarter. Revenue grew to $10.88M, while net loss attributable to stockholders widened to $11.34M and basic and diluted loss per share was $(0.38).

**Financial Highlights**

-   Revenue was $10.88M for Q2 2026, up from $9.215M in the year-ago quarter; YoY change 18%.
-   Net income (loss) attributable to stockholders was a loss of $11.337M for Q2 2026, versus a loss of $5.837M in the year-ago quarter (worse YoY).
-   Diluted earnings per share: Basic and diluted loss per share of $(0.38) for Q2 2026, versus $(0.21) in the year-ago quarter.

**Business Highlights**

-   Total revenue was up 30% year-to-date to $23.0M, driven by product sales across neurosurgery and capital equipment.
-   Neurosurgery revenue jumped 71% YTD, led by IRRAflow sales and adoption of OR navigation software v3.0.
-   Biologics services revenue remained steady, supported by a partner base of more than 60 that underpins recurring consulting and preclinical services.
-   Commercial expansion continued with increased placements of ClearPoint, IRRAflow control units and Prism lasers, expanding the company’s market footprint.
-   Operational scaling following the IRRAS integration expanded commercial and clinical teams and boosted investments in sales, marketing and R&D.

Original SEC Filing: ClearPoint Neuro, Inc. \[ CLPT \] - 10-Q - Aug. 03, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CLPT.US](https://longbridge.com/en/quote/CLPT.US.md)

## Related News & Research

- [Paratus Energy announces Q2 2026 cash dividend of USD 0.22 per share](https://longbridge.com/en/news/297268195.md)
- [Perma-Pipe International - Enters 2026 Credit Agreement With JPMorgan Chase Bank On August 25, 2026 - SEC Filing](https://longbridge.com/en/news/297184704.md)
- [Ameriprise Financial declares Q3 2026 dividend of R$ 1.48 per unit](https://longbridge.com/en/news/297021432.md)
- [Cognizant declares dividend of R$ 1.15 per unit for 3Q 2026 BDRs](https://longbridge.com/en/news/297326890.md)
- [SoftwareOne attaches full H1 2026 report in correction to earlier release](https://longbridge.com/en/news/297010247.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**